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Objective: To translate and adapt the Hip disability and Osteoarthritis Outcome Score (HOOS) into French
and to evaluate the psychometric properties of this new version, by testing feasibility, internal consis-
tency, construct validity, reliability and responsiveness, in patients with hip osteoarthritis (OA).
Methods: The French version of the HOOS was developed according to published international guidelines
to ensure content validity. The new version was then evaluated in two symptomatic hip OA populations,
one with no indication for joint replacement (medical group), and the other waiting for total hip
replacement (THR) (surgery group). The psychometric properties assessed were feasibility: percentage of
responses, ﬂoor and ceiling effects; internal consistency using Cronbach’s alpha; construct validity by
evaluating correlations with the Lequesne’s index and the visual analogic scale (VAS) for pain (Pearson’s
correlation coefﬁcient); reliability: intra-class correlation coefﬁcient (ICC), Bland et Altman representa-
tion; responsiveness by comparing the results of before and 1 month after injection of hyaluronic acid
(medical group) and by comparing the pre and 3 months post THR results (surgery group) by calculating
standardized response mean (SRM) and effect size (ES).
Results: A total of 88 patients were recruited; 58 in the medicine group (mean age¼ 61.8 9 years, range
42–81, 70% women) and 30 in the surgery group (mean age¼ 67.5 9 years, range 50–81, 68% women).
The percentage of item responses was excellent (99%). Neither a ﬂoor nor a ceiling effect was observed,
except for a ceiling effect (17.8% of patients with worst possible score) observed prior to surgery in the
sport and recreation subscale. The internal consistency was good for four of the ﬁve HOOS subscales. As
expected, the strongest correlations were observed between all HOOS subscales and Lequesne’s index or
VAS pain, indicating good construct validity. The reliability was good, with an ICC> 0.8 for all subscales.
The responsiveness was good for all domains 1 month after hyaluronic acid injection (ES ranging from
0.73 to 1.86 and SRM from 0.51 to 1.04) and high for all domains 3 months after THR (ES ranging from
1.47 to 2.08 and SRM ranging from 1.97 to 3.24).
Conclusion: The French version of HOOS demonstrated good psychometric properties and appears to be
useful for the evaluation of patient-relevant outcome whatever the severity of hip OA. This study
provides a basis for the use of this French version of the HOOS in future clinical trials.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Hip osteoarthritis (OA) is one of the leading causes of chronic
disability worldwide and has a signiﬁcant impact on patients’Paul Ornetti, Department of
Raines, 21000 Dijon, France.
tti).
Research Society International. Puhealth-related quality of life (QoL). Assessment of patients with hip
OA usually includes measurements of pain, functional impairment
and health-related QoL using disease-speciﬁc and generic health
status questionnaires1–4. The most widely used OA-speciﬁc
instrument is the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC)5 that covers pain, stiffness, and
functional limitation.blished by Elsevier Ltd. All rights reserved.
P. Ornetti et al. / Osteoarthritis and Cartilage 18 (2010) 522–529 523The Hip disability and Osteoarthritis Outcome Score (HOOS) is
a simple self-administered instrument developed as an extension
of the WOMAC for patients with hip OA or hip disability6–8. The
HOOS includes ﬁve domains, i.e., pain, other symptoms, activities of
daily living (ADL), sport and recreation function (SP) and hip related
QoL. The pain domain is constituted by the ﬁve questions of the
original WOMAC pain domain, plus ﬁve additional questions; the
other symptoms domain includes the two questions of theWOMAC
stiffness domain plus three additional questions on the presence of
hip noises, the difﬁculties to spread legs wide apart or to stride out
during walk; the ADL domain corresponds to the WOMAC function
(17 questions); the SP (four questions) and hip related QoL (four
questions about global difﬁculty, lack of conﬁdence in hip, lifestyle
change or awareness of the hip problem), are newly generated
domains6 which aim to evaluate the consequences of hip OA on
more demanding activities and on QoL. A normalized score can be
calculated for each domain (100 indicating no symptoms and
0 indicating extremes symptoms) and the results can be plotted in
an outcome proﬁle. The original version of the HOOS was shown to
be valid, reliable, and responsive in hip OA patients and is consid-
ered useful for the evaluation of patient-relevant outcomes7,8.
Due to the increase in the number of large multicenter interna-
tional studies and the requirement for globally meaningful epide-
miologic and/or therapeutic study results, there is a need for
cross-cultural adaptation and validation of health status measures9.
This speciﬁc process may require not only translation but also
substantial transformation of some items to fully capture the
essence of the original concept10,11. Ideally, a ﬁnal step aims to check
that the translated questionnaire has kept the psychometric prop-
erties of the original one, in particular those deﬁned by the OMER-
ACT (Outcome Measures in rheumatology) ﬁlter, i.e., truth (the
questionnaire reﬂectswhat it is supposed to), discrimination, which
includes reliability and sensitivity to change over time, and feasi-
bility. Validated versions of HOOS have been published for use in
Danish, Dutch12, German, English, Lithuanian and Swedish13. On the
basis of a systematic literature search for psychometric assessment
of OA-speciﬁc questionnaires, Veenhof concluded that the HOOS
questionnairewas one of the top three questionnaires, with the best
ratings for its psychometric properties to assess both pain and
functional impairment induced by hip OA14. Thus, there is a need for
translations into other languages and cross-cultural adaptations.
The aim of this study was to translate the HOOS questionnaire
into French and adapt it to cultural speciﬁcities, then to evaluate the
psychometric properties of the French version of the HOOS, as
expressed by its feasibility, internal consistency, reliability,
construct validity and responsiveness, in patients with symptom-
atic hip OA.
Methods
A two step procedure was used:
- Firstly, the instrument was translated and cross culturally
adapted into French language.
- Secondly, the psychometric properties of the adapted instru-
ment were studied in a prospective study by testing feasibility,
internal consistency, construct validity, reliability and
responsiveness.Translation and cross-cultural adaptation process
The translation and cross-cultural adaptation from the source
English version was performed according to published interna-
tional recommendations9–11.Preparation
The project manager (JFM) contacted the developer (ER) to
obtain permission to use and translate the instrument, to check that
no other translation in French was ongoing, and to propose to
participate in the work. Then, the project manager and the devel-
oper had a meeting to produce information about the conceptual
basis of some items, for use by the translators.
Forward translation
Three persons (two rheumatologists, including the project
manager, and one French-mother-tongue English teacher) inde-
pendently translated the English version of HOOS into French. Prior
to translation, the project manager provided the other translators,
in particular the non-rheumatologist translator, with information
about the disease, the conceptual basis of measurement, and
information obtained from the developer.
Reconciliation
A ﬁnal single version was obtained after a consensus meeting of
the three translators.
Backward translation
The ﬁnal consensus version was literally back translated into
English by a bilingual native English speaker, blinded to the original
English version.
Back translation review and harmonization
The project manager reviewed the back translation against the
source, in order to check for discrepancies. Then, a multidisci-
plinary consensus committee, including the three translators,
another rheumatologist (PO), an orthopedic surgeon (YJ), and
a rheumatologist and epidemiologist specialized in cross-cultural
adaptation (FG), was constituted. The committee had a meeting in
order to perform another back translation review, as well as to
conduct the harmonization step. During the meeting, the
committee checked that the translation was fully comprehensive,
veriﬁed cross-cultural equivalence of the source and ﬁnal versions,
and by consensus produced a ﬁnal version.
Cognitive debrieﬁng and review
The ﬁnal version was pre-tested in 15 French outpatients
visiting the rheumatology department of the Dijon University
Hospital for hip OA, with characteristics comparable to those of the
patients included in the second part of the study. The patients
completed the questionnaire in the presence of one of the rheu-
matologists involved in the project. They were asked whether they
fully understood all items and whether they had problems with the
formulation of the items of the French version. The results of the
cognitive debrieﬁng were reviewed by the project manager. When
appropriate, the initial translation was modiﬁed.
Proof reading
In the ﬁnal step, the project manager checked the ﬁnal trans-
lation and corrected any error. During the whole process, the
participants were instructed to keep in mind that the ﬁnal wording
needed to be understood by non-specialists as well as individuals
with a low level of education (grade 6,10–12 years old). At any time,
the project manager had the possibility to contact the developer to
discuss conceptual problems.
Psychometric properties of the French version of HOOS
Data collection
Patients. Two study populations with hip OA were evaluated in
a bicentric prospective study. The medical group comprised
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in the rheumatology department of Dijon University Hospital
(France). The surgery group was recruited from the orthopedic
surgery department of Marseille University Hospital (France).
The inclusion criteriawere age of at least 40 years, primary hipOA
according to the American College of Rheumatology criteria15 and
ability to understand and complete self-report questionnaires. In
patients evaluated for responsiveness in the medical group, an
additional inclusion criterion was the indication for intra-articular
hyaluronate injection, according to the rheumatologist’s usual prac-
tice. Inpatients evaluated for responsiveness in the surgerygroup, an
additional inclusion criterion was the indication for total hip
replacement (THR) retained by the attending orthopedic surgeon.
The exclusion criteria were the presence of other signiﬁcant
rheumatic diseases such as symptomatic OA in other lower limb
joints, severe inﬂammatory arthritis and secondary hip OA and/or
low back pain and the intra-articular use of corticosteroids within
the previous 3 months. In patients evaluated for reliability, an
additional exclusion criterion was expected changes in knee or hip
OA treatment during the following 2 weeks. In patients evaluated
for responsiveness in the medical group, an additional exclusion
criterion was expected changes in knee or hip OA treatment during
the following month, except for hyaluronate injection.
Questionnaires
Medical group. During the initial assessment, patients were asked
to complete the French version of the HOOS questionnaire,
Lequesne’s index, and a visual analogic scale (VAS) for pain. Each
HOOS item includes ﬁve answer options (Likert boxes) giving
a score from 0 to 4. For each domain, scores are normalized from
worst to best on a 0–100 scale. Missing values were handled
according to HOOS guidelines6,13: whenmore than two of the items
of a domain were missing, the score was not calculated. In other
situations, missing values were replaced by the average of values
observed in the same domain for the individual. Lequesne’s
index16,17 is a disease-speciﬁc questionnaire comprising 10 items
that assess pain and functional disability in hip OA. The total
questionnaire, scored on a 0–24 scale, with lower scores meaning
less functional impairment, is a commonly used outcome measure
in lower limb OA. The VAS for pain is a widely used, valid and
reliable way to measure pain intensity1.
Patients evaluated for reliability were given a second HOOS
questionnaire that was completed and returned by mail 2 weeks
later, using a pre-stamped envelope. Two weeks were considered
long enough to ensure that patients would not remember what
they responded to the ﬁrst questionnaire, and sufﬁciently short to
ensure that no signiﬁcant change in hip OA pain and disability
would occur.
Patients evaluated for responsiveness were given one ultra-
sound-guided intra-articular injection of hyaluronic acid. The
procedure was performed by the same physician (PO). The hya-
luronic acid varied in nature and molecular weight since the
patients presented with a speciﬁc prescription from their treating
rheumatologist. The patients were given a second HOOS ques-
tionnaire, which they were asked to complete 1 month later and
mail back using a pre-stamped envelope.
Surgery group. These patients were evaluated for responsiveness
following THR. They were asked to complete a HOOS questionnaire
before the operation, and during a follow-up visit, 3 month after
surgery.
Data analysis
Feasibility. Feasibility was assessed using the percentages of
responses and using the ﬂoor and ceiling effects in both themedicaland surgery group. The presence of ﬂoor and ceiling effects may
inﬂuence the reliability, validity and responsiveness of an instru-
ment. In this study, ﬂoor and ceiling effects were considered
present if more than 15% of the respondents achieved the highest or
lowest score.
Internal consistency. Internal consistencymeasures the correlations
between different items on the same subscale and their degree of
homogeneity. The internal consistency was assessed using Cron-
bach’s alpha coefﬁcient18, with 95% Feld’s conﬁdential intervals
(95% CI). There are discrepancies in the literature regarding which
cut-off should be used to deﬁne a satisfactory Cronbach’s alpha
coefﬁcient19,20. In the present study, a threshold of 0.7 was used,
i.e., coefﬁcients 0.7 were considered as satisfactory20.
Construct validity. In the medical group, the construct validity was
assessed by correlating the results of the ﬁve HOOS subscales with
Lequesne’s index and the VAS for pain. As recommended in the
literature21, Pearson’s correlation coefﬁcients of >0.50, 0.35–0.50,
and <0.35 were considered strong, moderate, and weak, respec-
tively. A priori hypotheses were that all HOOS domains would
strongly correlate with Lequesne’s index and the pain VAS. In
addition, it was hypothesised that the highest correlations would
be observed between scales that are intended to measure similar
constructs, i.e., VAS pain vs HOOS pain and Lequesne vs function
ADL and function SP.
Reliability. The reliability of the HOOS subscales was assessed using
the intra-class correlation coefﬁcient (ICC) (two way model, single
measure), with 95% CI. An ICC of more than 0.80 is usually
considered an indicator of good reliability22,23.
In addition, the Bland and Altman representation24, inwhich the
difference between the ﬁrst and the second assessment are plotted
against the mean of the two assessments, was obtained. This
representation makes it possible to describe the percentage of
subjects and their distribution within the 95% limits of agreements
along the score scale.
The smallest detectable difference (SDD), which corresponds to
the limits of agreement (mean change 1.96 standard deviation
(SD) change) was obtained. The SDD indicates the smallest change
that can be distinguished from the measurement error24,25.
Responsiveness. Responsiveness was evaluated by comparing the
pre and 1-month post hyaluronic acid injection results, as well as by
comparing the pre and 3 months post THR results. The standard-
ized response mean (SRM), i.e., the mean change between baseline
and follow-up divided by the SD of this change, and the effect size
(ES), i.e., the mean score change between baseline and follow-up
divided by the SD of the baseline values, were calculated.
The Statistical Package for the Social Sciences (SPSS) version 14.0
was used for statistical analyses. The level of signiﬁcance for all
statistical procedures was P< 0.05.
Results
Translation process
Only slight differences were identiﬁed in the structure of the
sentences between the three translations, as well as between the
original and back-translated versions. Before reaching a consensus,
the committee discussed at length the adaptation of words to
maintain meaning and the correct wording to allow the question-
naire to be fully understood by all patients. A large majority of
patients felt that the questionnaire was clear and easy to complete.
In some instances, it was necessary to specify that the questions
Table I
Internal consistency of the ﬁve HOOS subscales, N¼ 88
HOOS subscales (number of items) Cronbach’s alpha coefﬁcient (95% CI)
Pain (10) 0.86 (0.79–0.91)
Symptoms (5) 0.66 (0.52–0.76)
Function act. daily living (17) 0.94 (0.91–0.96)
Function sport/recreation (4) 0.85 (0.78–0.90)
QoL (4) 0.82 (0.74–0.88)
95% CI: conﬁdence interval.
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questionnaire contained too many questions. No modiﬁcations
were made to the questionnaire following the cognitive debrieﬁng
process.
Patients’ characteristics
A total of 88 patients were recruited; 58 in the medicine group
(mean age¼ 61.8 9 years, range 42–81, 70% women) and 30 in the
surgery group (mean age¼ 67.5 9 years, range 50–81, 68%
women).
The samples used to evaluate the psychometric properties were
as follows:
- Feasibility was obtained using the ﬁrst questionnaire
completed by all 88 patients.
- Internal consistency was evaluated using the ﬁrst question-
naire completed by the 88 patients.
- Construct validity was evaluated on 32 patients from the
medicine group from whom the VAS for pain and the
Lequesne’s index were obtained, in addition to the HOOS.
- Reliability was evaluated using questionnaires from 43 out of
58 patients from the medicine group. All patients completed
and mailed back their second questionnaire. The remaining
patients (15/58) were administrated hyaluronic injection at the
ﬁrst visit, so were excluded for this particular assessment.
- The evaluation of responsiveness included the 30 patients of
the surgery group on one hand, 21 patients from the medicine
group on the other hand. These 21 patients were the 15 who
were given intra-articular hyaluronic injection at the ﬁrst visit,
plus six additional patients who participated to the reliability
evaluation, then were treated with hyaluronic acid injection.
Most patients (28 out of 30 in the surgery group and 21 out of
21 in the medicine group) completed and mailed back their
second questionnaire.Psychometric properties
Feasibility
In the medical group and the surgery group prior to THR (88
patients), few responses to HOOS items were missing (0.9% and
1.32% respectively), and the total scorewas obtained for all domains
in all patients. No ﬂoor or ceiling effect was observed in the medical
group. In the surgery sample, however, a ceiling effect was observed
prior to surgery in the sport and recreation subscale (17.8% of
patients with worst possible score). An additional evaluation
showed that this ceiling effect had disappeared after THR (0%).Table II
Construct validity determined as Pearson’s correlations between each subscale of the Fr
HOOS Pain Symptoms
Pain (VAS) 0.67 (P< 0.001) 0.49 (P¼ 0.004)
Lequesne’s index 0.68 (P< 0.001) 0.54 (P¼ 0.002)
ADL: activities of daily living.Internal consistency
Table I presents the internal consistency for the 88 patients
(medical and surgery group). Cronbach’s alpha ranged from 0.82 to
0.94, indicating good homogeneity, except for the symptoms
subscale for which the coefﬁcient was below 0.7 (0.66, 95%
CI¼ 0.53–0.76). Internal consistency of the WOMAC stiffness score
(which is embedded within the HOOS symptoms subscale) was
poor (0.50). Cronbach’s alpha was equivalent between the WOMAC
pain score (0.81) and the HOOS pain subscale (0.86).
Construct validity
Table II shows the correlations between the scores of HOOS
subscales, Lequesne’s index and VAS pain. Strong correlations were
observed between all HOOS subscales and Lequesne’s index or VAS
pain. As expected, the highest correlations were found between
scales that measure similar constructs (Lequesne vs function ADL
(r¼0.69) or vs function SP (r¼0.82)). Interestingly, the corre-
lation between VAS pain and HOOS pain was high (r¼0.67), as
expected, and was comparable to the correlation between VAS Pain
and HOOS function ADL (r¼0.71).
Reliability
For all HOOS subscales, the ICCs were good, ranging from 0.83
(pain subscale) to 0.89 (sports and recreation function subscale)
(Table III). The Bland and Altman graphic representations are shown
in Fig. 1. The difference between repeated measurements was
includedwithin the limits of agreements inmost cases, andwas not
related to themean of the twomeasurements. The SDD ranged from
9.6 (function ADL subscale) to 16.2 (QoL subscale) (Table III). Reli-
ability was similar between the WOMAC pain score (ICC 0.81) and
the HOOS pain subscale (0.83) and between the WOMAC stiffness
score (ICC 0.82) and the HOOS symptoms subscale (0.84).
Responsiveness
Surgery group. All HOOS subscale scores improved signiﬁcantly
(P< 0.001) postoperatively as compared to preoperative scores
(Fig. 2a). The responsiveness was high for all domains, with SRM
ranging from 1.97 to 3.24 and ES from 1.47 to 2.08 (Table IV). The
QoL domain appeared to be less responsive than the other
subscales (Fig. 2).
Medical group. The responsiveness was high for all domains 1
month after hyaluronic acid injection with SRM ranging from 0.51
and 1.04, and ES ranging from 0.73 to 1.86 (Table IV). The change in
sport and recreation subscale appeared to be less than the change
in other subscales (Fig. 2b).
The responsiveness was statistically higher (P< 0.05) for the
HOOS pain subscale in each group (ES 1.86 for hyaluronic acid
injection and ES 3.24 for THR) than for the WOMAC pain score (ES
1.25 for hyaluronic injection and 2.51 for THR). Moreover, the
responsiveness was higher for the HOOS symptoms subscale than
for the WOMAC stiffness score in each group, but without reaching
statistical signiﬁcance.
Discussion
In the present work, the English version of HOOS was cross
culturally adapted into French. The psychometric properties of theench HOOS and pain as measured by VAS and Lequesne’ index, N¼ 32
Function ADL Sport recreation QoL
0.71 (P< 0.001) 0.58 (P< 0.001) 0.55 (P¼ 0.001)
0.69 (P< 0.001) 0.82 (P< 0.001) 0.51 (P¼ 0.003)
Table III
Mean HOOS scores at the ﬁrst and second assessment and the test–retest reliability
given as ICCs, N¼ 43








ICC (95% CI) SDD
Pain 55.3 (14.2) 52 (13.7) 0.83 (0.70–0.90) 15.1
Symptoms 54.1 (14.9) 52.9 (14.5) 0.84 (0.72–0.91) 10.5
Function ADL 53.9 (16.3) 53 (15.9) 0.86 (0.76–0.92) 9.6
Function sport/recreation 34.6 (20.4) 33.5 (20.5) 0.89 (0.80–0.94) 15.5
QoL 37.5 (19.5) 38.2 (18.3) 0.86 (0.76–0.92) 16.2
0¼worst to 100¼ best.
ADL: activities of daily living.
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similar to the original HOOS. The French version of the HOOS is not
copyrighted and will be downloaded for free on the KOOS website
(www.KOOS.nu)13.
All questionnaires have been completed and the low percentage
of missing data reﬂects the good acceptance and feasibility of the
French HOOS.
The results of internal consistency were excellent for four of the
ﬁve subscales and comparable to those observed in other
languages8,12. In line with previous validation studies, the highest
Cronbach’s alpha was found for the ADL subscale. Although
acceptable, internal consistency for the Symptoms subscale was
markedly lower (0.66) than that observed for other subscales
(>0.82). This unexpected result might indicate lower inter-itemFig. 1. Reliability of the French HOOS subscales presented as Bland and Altman represen
agreement correspond to the mean difference between two measurements 1.96 SD. (a) Pa
recreation activity subscale and (e) QoL subscale.correlation in this subscale. Contrary to the subscale pain, the
subscale symptoms might capture more than one concept (type of
hip noises, difﬁculties or stiffness related to hip OA) and, thus, this
multidimensional construct requires cautious interpretation of the
internal consistency. However this result was not reported previ-
ously (the lowest Cronbach’s alpha was found for the QoL subscale
in the Swedish version of HOOS7 and for the Pain subscale in the
Dutch version12). An alternative explanation might be a problem in
the translation and cross-cultural adaptation into French. However,
such a result was not observed in a previous study evaluating the
psychometric properties of the French KOOS, in which the Symp-
toms subscale’s internal consistency was good26, while several
questions of both subscales (HOOS and KOOS Symptoms) are
common or very close to each other. Finally, the explanation might
be variations between samples: in the present study, the 95% CI of
the Symptoms subscale included 0.7.
Whatever the explanation, it is not currently possible to state
that the French version of the Symptoms subscale can be consid-
ered as a homogeneous subscale. Further studies are needed to
respond to this question. Waiting for these, the symptoms subscale
of the French HOOS should be used at the group level rather than at
the individual level (that needs a high level of internal
consistency27).
The mean scores of the two subscales that are not included in
theWOMAC (Sport and recreation function subscale and QoL) were
markedly lower than the scores of other HOOS subscales consistent
with previous reports8,12. This might be related to the age of our
patients (mean age¼ 68). The test–retest reliability coefﬁcients
were high (ICC> 80) for all HOOS subscales, in accordance withtations. Two assessments, separated by a 2-week interval, were made. 95% limits of
in subscale, (b) symptoms subscale, (c) activity of daily living subscale, (d) sports and
Table IV
Responsiveness of French HOOS subscales
HOOS subscales THR, N¼ 30 Hyaluronic acid N¼ 21
Pre mean (SD) Post mean (SD) ES SRM Pre mean (SD) Post mean (SD) ES SRM
Pain 41.7 (13.8) 86.5 (16.1) 3.24 1.85 43.6 (15.7) 59.0 (17.5) 1.86 0.99
Symptoms 41.0 (17.0) 77.3 (14.2) 2.14 1.54 38.8 (16.0) 55.5 (19.7) 1.22 1.04
Function ADL 38.7 (14.7) 81.8 (13.5) 2.83 2.08 40.6 (16.2) 55.6 (18.0) 1.47 0.92
Function sport/recreation 18.3 (14.6) 64.0 (19.7) 3.11 1.90 29.5 (22.8) 41.1 (27.2) 0.73 0.51
QoL 21.4 (20.7) 61.4 (21.2) 1.97 1.47 33.9 (20.4) 48.8 (19.0) 1.00 0.73
Thirty patients were evaluated prior to and 3 months after THR.
Twenty one patients were evaluated prior to and 1 month after one ultrasound-guided intra-articular hyaluronic acid injection.
0¼worst to 100¼ best.
ADL: activities of daily living.
P. Ornetti et al. / Osteoarthritis and Cartilage 18 (2010) 522–529 527previous studies. According to the Bland and Altman representa-
tions, the difference between repeated measurements was not
related to the mean of the measurements.
Construct validity was satisfactory. All HOOS domains correlated
strongly with Lequesne’s index and VAS pain, with higher corre-
lations between scales that are intended to measure similar
constructs, as expected.Fig. 2. Responsiveness of French HOOS. (a) HOOS subscales prior to and 3 months after T
articular hyaluronic acid injection. This scale is 0–100, worst to best.Responsiveness is a crucial psychometric property of
a measurement instrument since high responsiveness makes it
possible to reduce the number of subjects needed to demonstrate
a signiﬁcant difference between groups. In this study, HOOS
responsiveness was good in the two evaluated samples. This result
was expected in the surgery group since THR is a highly effective
intervention in hip OA, and since the responsiveness of the HOOSHR and (b) HOOS subscales prior to and 1 month following ultrasound-guided intra-
P. Ornetti et al. / Osteoarthritis and Cartilage 18 (2010) 522–529528questionnaire has been found to be excellent in other THR pop-
ulations in other languages8,12. In contrast, to our knowledge, the
responsiveness in patients treated with intra-articular hyaluronic
acid injection had not been evaluated. Since this intervention is
less effective than THR, and has not been found to be superior to
placebo injection28,29, null or low SRM and ES might have been
expected, while the results demonstrated good responsiveness.
However, responsiveness results of cases series studies of HA
injections remains difﬁcult to interpret due to small patient
numbers, lack of controls, co-interventions, placebo response, and
lack of blinding of injectors30. Some of the change might have been
due to a placebo effect31, which has been shown to be prominent in
OA, particularly from injections. Moreover, in the medical group,
the second assessment 1 month after HA injection might explain
the high placebo response, as noticed in a previous study32 in
which 25% of patients in the placebo group were considered as
responders at 1 month but only 4.8% at 3 months post-treatment.
Moreover, difference between groups in analgesics or NSAIDs
intake might limit the ability to compare the responsiveness
between THR and hyaluronic injection. Nevertheless, the aim of the
present study was not to evaluate the effectiveness of hyaluronic
injections in hip OA patients, but to assess the psychometric
properties of a questionnaire. In that objective, the results are very
satisfactory and suggest that the French HOOS can capture less
prominent changes than those observed following THR and is
a suitable instrument to be used in therapeutic trials. Moreover, the
results of this study show that the HOOS has a higher respon-
siveness than the WOMAC for these patients and may be useful in
evaluating hip OA and intervention outcome in different groups of
patients.
This study has some limitations: ﬁrstly, participating subjects
might not represent the entire spectrum of patients with hip OA as
they were recruited from two University Hospitals and were likely
to have more severe OA, in particular the surgery group is over
representing severe OA. This might explain in part the ceiling effect
detected in the surgery group prior to THR for the sport and
recreation subscale, which was originally developed for younger,
more active patients. This effect has been also observed in the
original HOOS study8. Further studies evaluating other sub-pop-
ulations of hip OA are needed before generalization. Secondly, the
brief interval between baseline and follow-up to evaluate sensi-
tivity to change (1month for hyaluronic acid injection, 3months for
surgery) might appear insufﬁcient. However, the SRM and ES
observed in the present study were satisfactory and did not
compromise the results.
In the last decade, the need to translate and cross culturally
adapt patient reported outcome developed in English speaking
countries has grown rapidly for use in international clinical trials. In
the present study, a French version of the HOOS questionnaire was
obtained and evaluated according to the principles of good practice
for the translation and cultural adaptation process for patient
reported outcomes9–11. The French HOOS demonstrated good
psychometric properties and appears to be useful for the evaluation
of patient-relevant outcome whatever the degree of severity of hip
OA. Although the internal consistency of the Symptoms domain has
to be further evaluated, this study provides a basis for the use of this
French version of the HOOS for future clinical trials using this
instrument.
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